Question explored with the scientific record
Conversation so far
- 1 What is the mechanis for improving cardiac output
- 2 How does Marianne improve cardiac output
- 3 How does Jardiance improve cardiac output
Answered on this page ↓
How does Jardiance improve cardiac output
The short version: Jardiance doesn't work like a squeeze. It cuts heart failure hospitalizations and heart death, but the trials measured events, not cardiac output.
No retrieved study measured cardiac output on Jardiance. The best human evidence is on hard outcomes: in EMPA-REG, empagliflozin cut the combined heart attack, stroke, and death endpoint by 14%, mostly through a 38% drop in cardiovascular death, with a 35% drop in heart failure hospitalization [3]. In EMPEROR-Reduced, it reduced cardiovascular death or heart failure hospitalization in reduced-ejection-fraction patients regardless of diabetes [5]. A pooled analysis of 38 trials found heart failure hospitalizations down 26% and cardiovascular death down 14% [8]. None of that is a cardiac output number.
The mechanism people point to is direct and mitochondrial, not hemodynamic. In non-diabetic mice with pressure-overload failure, empagliflozin preserved systolic function and improved mitochondrial function and oxidative stress without changing blood glucose or weight [1][7]. That is mouse data, and mice are not people.
| Finding | What it shows | Source |
|---|---|---|
| EMPA-REG: 14% fewer MACE, 38% fewer CV deaths | Hard outcomes, not output | [3] |
| EMPEROR-Reduced: fewer CV deaths/HF hospitalizations | Hard outcomes, not output | [5] |
| Pooled 38 trials: HF hospitalizations RR 0.74 | Hard outcomes, not output | [8] |
| Mouse pressure-overload: preserved systolic function | Mechanism, animal only | [1][7] |
| EMBLEM: no endothelial function improvement | Mechanism not confirmed in humans | [2] |
The honest gap: the human trials that would show a direct cardiac output or ejection fraction effect are thin here. One small observational study saw ejection fraction categories shift upward after SGLT2 inhibitors, but it had no control group and inconsistent numbers [6]. A real-world 31-patient study saw ejection fraction rise from about 33% to about 39% at 12 months, but it was nonrandomized [4]. That is suggestive, not proof.
My call: Jardiance clearly reduces heart failure hospitalizations and cardiovascular death in the right patients, but the claim that it "improves cardiac output" is not established by these records, and the mechanism is more likely metabolic and mitochondrial than a pump effect. Confidence: moderate on the outcome benefit, low on the cardiac output claim.
Sources used 8
-
Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
In nondiabetic mice with established pressure-overload heart failure, empagliflozin treatment prevented the progressive decline in systolic function and preserved ex vivo cardiac function without altering cardiac remodeling or diastolic function.
DOI: 10.1016/j.jacbts.2017.07.003 -
Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial
A post-hoc analysis of the EMBLEM trial in Japanese patients with type 2 diabetes and established cardiovascular disease found that 24 weeks of empagliflozin did not improve peripheral endothelial function (RHI) compared with placebo, despite favorable metabolic/hemodynamic effe…
DOI: 10.1111/jdi.13289 -
SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
SGLT2 inhibitors combined with metformin plus a second or third agent consistently lower HbA1c more than either drug alone, but glycemic effects are subadditive rather than synergistic, while pleiotropic effects such as blood pressure differ by partner drug.
DOI: 10.2337/dc18-0588 -
Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study
A 12-month real-world study in 31 Italian patients with type 2 diabetes and heart failure with reduced ejection fraction (HFrEF) treated with SGLT2 inhibitors (empagliflozin or dapagliflozin) showed significant improvements in right-ventricular remodeling and pulmonary hemodynam…
DOI: 10.3390/ph18081200 -
SGLT2 Inhibitors: A Promising New Tool in Cardiology
SGLT2 inhibitors have demonstrated cardiovascular benefits extending beyond glucose control, showing reduced major adverse events in type 2 diabetes and significant benefits in heart failure patients, though consistency varies across trials.
DOI: 10.33140/ijdmd.08.03.09 -
EVALUATION AND EFFICACY OF SGLT2 INHIBITORS IN DIABETES MELLITUS AND HEART FAILURE PATIENTS IN TELANGANA
In a 110-patient prospective observational study in Telangana, SGLT2 inhibitor therapy was followed by a significant shift toward higher LVEF categories (chi-square p=2.304×10−9), but glycemic and EF magnitude reports were inconsistent.
DOI: 10.59551/ijhmp/25832069/2025.6.2.115 -
Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
In a non-diabetic mouse model of pressure overload-induced heart failure, four weeks of empagliflozin improved mitochondrial function and reduced oxidative stress through direct cardiac effects, attenuating remodeling and improving cardiac function without changing blood glucose…
DOI: 10.3389/fcvm.2022.859253 -
Efficacy of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure Management: A Narrative Review
This narrative review reports pooled randomized-trial estimates that SGLT2 inhibitors reduce heart failure hospitalizations and cardiovascular mortality overall, with greater benefit in HFrEF and limited HFpEF mortality benefit.
DOI: 10.61919/jhrr.v4i3.1573